Join to access to all OVN content. Join for Free
What I DO….How I BUILD Relationships
Medical Science Liaison KOL relationships MSL Society professional development digital engagement

What I DO….How I BUILD Relationships


Share This Article


Summary

In this episode, Bernadett Mamone shares her educational and professional journey in the medical affairs landscape. She highlights the secrets to becoming a successful MSL, emphasizing the importance of continuous learning and professional development through organizations like HBA, MSL Society, and Toastmasters. Bernadett delves into strategies for developing strong KOL relationships and effective communication, while also addressing the significance of digital engagement. She offers advice on networking, avoiding common MSL mistakes, and maintaining mental clarity. The episode concludes with insights on leveraging additional platforms for professional growth.

My guest today is Bernadett Mamone, PhD, MEd, MSL-BC, Medical Science Liaison at Neurelis, and we discuss her best practices on being a successful MSL and how she builds KOL relationships

Bernadett shares…

👉 What is most important to being a top MSL
👉 Which resources are most valuable as you develop a career as an MSL
👉 Why Toastmasters was a huge help and valuable resource
👉 What some of the key tips are for developing strong relationships with KOLs
👉 Some of the most common mistakes MSLs make
👉 What skills need to be developed for MSLs to achieve success and get to the next level

Click for Source
Medical Science Liaison, KOL relationships, MSL Society, professional development, digital engagement

Related Topics

Meet Our Innovation Partners

Loading partners...

You May Also Like

Podcast
Social Media Listening Evolved
Partner Avatar MSL Talk: Tom Caravela, Conor McGladrigan, Kevin Peterson

Social Media Listening Evolved

Podcast
Over-Negotiation-How to Botch a Job Offer
Partner Avatar MSL Talk: Tom Caravela

Over-Negotiation-How to Botch a Job Offer

Article
Virtual Clinical Trials in Oncology-Overview, Challenges, Policy Considerations, and Future Directions
OVN Avatar Kushal T. Kadakia, MSc, Malke Asaad, MD, Erica Adlakha, MS, Michael J. Overman, MD, Cristina M. Checka, MD, and Anaeze C. Offodile II, MD, MPH

Virtual Clinical Trials in Oncology-Overview, Challenges, Policy Considerations, and Future Directions

Article
Comparative study on anticancer drug access times between FDA, EMA and the French temporary authorisation for use program over 13 years
OVN Avatar Emmanuelle Jacqueta, Ghania Kerouani-Lafayeb, Francoise Grudeb, Sergio Goncalvesb, Annie Lorenced, Florence Turcryb, Liora Brunelb, Laetitia Belgodereb, Adrien Monardc, Gaëlle Guyaderb, Lotfi Boudalib, Nicolas Albin

Comparative study on anticancer drug access times between FDA, EMA and the French temporary authorisation for use program over 13 years

Article
Evaluation of Trials Comparing Single-Enantiomer Drugs to Their Racemic Precursors: A Systematic Review
OVN Avatar Aaron S. Long, BS; Audrey D. Zhang, MD; Caitlin E. Meyer, MLIS; Alexander C. Egilman, BS; Joseph S. Ross, MD, MHS; Joshua D. Wallach, PhD, MS

Evaluation of Trials Comparing Single-Enantiomer Drugs to Their Racemic Precursors: A Systematic Review

Article
Transforming oncology: Five frontiers driving progress in cancer care
Partner Avatar iNIZIO

Transforming oncology: Five frontiers driving progress in cancer care

Explore OVN